Radiopharm Theranostics shareholders vote on Paul Hopper, Ian Turner, Bruce Goodwin, Riccardo Canevari director SPP allocations at Sept. 11 meeting

• Radiopharm Theranostics shareholders vote Sept. 11, 2026 on a capital raising package spanning placements, an SPP, options, and US warrants.
• Ratification sought for 408,839,531 placement shares issued at AUD 0.015 on Aug. 3, 2026.
• Approval requested for up to 40,000,000 second-tranche placement shares at AUD 0.015, up to 448,839,531 attaching options at AUD 0.018.
• SPP authority covers up to 666,666,667 shares priced at the lower of AUD 0.015 or a 2.5% VWAP discount.
• Director participation vote covers Paul Hopper, Ian Turner, Bruce Goodwin, Riccardo Canevari with SPP shares, matching SPP attaching options.
• Additional votes cover 200,000,000 shortfall options, 1,281,646 ADR warrants, 64,082 agent warrants; board recommends voting in favor of all resolutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-088705), on August 13, 2026, and is solely responsible for the information contained therein.